Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BASINASDAQ:CBLIOTCMKTS:CBWTFNASDAQ:ELOXNASDAQ:PIRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBASIBioanalytical Systems$2.09+3.2%$18.71$3.05▼$21.08$23.26M1.92122,925 shs268,139 shsCBLICleveland BioLabs$3.19$1.62▼$10.97$5K0.7271,922 shs2,555 shsCBWTFCannabis Wheaton Income$0.09+14.5%$0.06$0.02▼$0.10$120.75M1.04851,070 shs941,075 shsELOXEloxx Pharmaceuticals$0.11$0.00▼$0.84N/A-1536.271,618 shsN/APIRSPieris Pharmaceuticals$13.60$15.17$6.20▼$18.68$17.95M0.6185,715 shs51,728 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBASIBioanalytical Systems+7.71%+11.88%-25.28%-26.63%+25.78%CBLICleveland BioLabs0.00%0.00%0.00%0.00%-50.00%CBWTFCannabis Wheaton Income+14.50%+36.72%+51.40%+53.69%+312.61%ELOXEloxx Pharmaceuticals0.00%0.00%0.00%0.00%-99.99%PIRSPieris Pharmaceuticals0.00%0.00%0.00%0.00%+56.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBASIBioanalytical SystemsN/AN/AN/AN/AN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AN/AN/AN/AN/ACBWTFCannabis Wheaton Income0.7815 of 5 stars0.05.00.00.00.00.01.3ELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBASIBioanalytical Systems 0.00N/AN/AN/ACBLICleveland BioLabs 0.00N/AN/AN/ACBWTFCannabis Wheaton Income 0.00N/AN/AN/AELOXEloxx Pharmaceuticals 0.00N/AN/AN/APIRSPieris Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBASIBioanalytical Systems$60.47M0.38$0.00 per share558.40$0.69 per share3.03CBLICleveland BioLabs$260K0.00N/AN/A$0.87 per share0.00CBWTFCannabis Wheaton Income$89.29M1.35N/AN/A$0.06 per share1.53ELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/AN/APIRSPieris Pharmaceuticals$42.81M0.42N/AN/A$21.66 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBASIBioanalytical Systems-$4.68M-$0.35N/A52.25N/A-7.75%-42.74%-6.38%N/ACBLICleveland BioLabs-$2.40MN/A0.00N/AN/AN/A-32.84%-31.29%N/ACBWTFCannabis Wheaton Income-$11.93M$0.019.17∞N/A16.56%18.53%8.13%N/AELOXEloxx Pharmaceuticals-$36.06MN/A0.00N/AN/AN/AN/AN/AN/APIRSPieris Pharmaceuticals-$24.54M-$12.10N/A∞N/A-39.71%-80.93%-59.55%N/ALatest BASI, CBWTF, ELOX, PIRS, and CBLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CBWTFCannabis Wheaton IncomeN/A$0.01N/A$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBASIBioanalytical SystemsN/AN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AN/ACBWTFCannabis Wheaton IncomeN/AN/AN/AN/AN/AELOXEloxx PharmaceuticalsN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBASIBioanalytical Systems2.490.480.46CBLICleveland BioLabsN/A45.9345.93CBWTFCannabis Wheaton Income0.020.680.34ELOXEloxx PharmaceuticalsN/AN/AN/APIRSPieris PharmaceuticalsN/A4.824.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBASIBioanalytical Systems10.62%CBLICleveland BioLabs5.09%CBWTFCannabis Wheaton IncomeN/AELOXEloxx Pharmaceuticals2.90%PIRSPieris Pharmaceuticals40.11%Insider OwnershipCompanyInsider OwnershipBASIBioanalytical Systems11.46%CBLICleveland BioLabs1.03%CBWTFCannabis Wheaton Income4.60%ELOXEloxx Pharmaceuticals20.20%PIRSPieris Pharmaceuticals6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBASIBioanalytical Systems39711.13 millionN/ANot OptionableCBLICleveland BioLabs415.48 millionN/ANot OptionableCBWTFCannabis Wheaton Income3691.32 billion1.26 billionNot OptionableELOXEloxx Pharmaceuticals303.14 million2.51 millionNot OptionablePIRSPieris Pharmaceuticals1401.32 million1.24 millionOptionableBASI, CBWTF, ELOX, PIRS, and CBLI HeadlinesRecent News About These CompaniesPieris Pharmaceuticals IncApril 18, 2025 | money.usnews.comPalvella Therapeutics Inc (PVLA)December 27, 2024 | investing.comOne new option listing and one option delisting on December 16thDecember 17, 2024 | markets.businessinsider.comMain Line biotech firm completes reverse merger, raises $78.9 millionDecember 17, 2024 | bizjournals.comPalvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease TreatmentsDecember 14, 2024 | msn.comPalvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 MillionDecember 14, 2024 | markets.businessinsider.com(PIRS) Trading ReportNovember 27, 2024 | news.stocktradersdaily.comNPIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRSNovember 20, 2024 | businesswire.comHow To Trade (PIRS)November 17, 2024 | news.stocktradersdaily.comNPieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trialNovember 7, 2024 | markets.businessinsider.com(PIRS) Investment Analysis and AdviceNovember 6, 2024 | news.stocktradersdaily.comNPieris loses Servier as partner for cancer immunotherapiesOctober 29, 2024 | pharmaphorum.comP(PIRS) Technical DataOctober 26, 2024 | news.stocktradersdaily.comNAridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comLearn to Evaluate (PIRS) using the ChartsOctober 16, 2024 | news.stocktradersdaily.comNPalvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual ConferenceOctober 15, 2024 | globenewswire.com(PIRS) Trading SignalsOctober 7, 2024 | news.stocktradersdaily.comNPalvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic MalformationsOctober 3, 2024 | globenewswire.comKubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comPieris Pharmaceuticals Inc.September 24, 2024 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBASI, CBWTF, ELOX, PIRS, and CBLI Company DescriptionsBioanalytical Systems NASDAQ:BASIBioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.Cleveland BioLabs NASDAQ:CBLICytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.Cannabis Wheaton Income OTCMKTS:CBWTF$0.09 +0.01 (+14.50%) As of 07/3/2025 12:59 PM EasternAuxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.Eloxx Pharmaceuticals NASDAQ:ELOXEloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.Pieris Pharmaceuticals NASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
